Breaking News Instant updates and real-time market news.

GMXAY

Genmab ticker changed to GMAB

$0.00

(0.00%)

, MOR

MorphoSys

$29.63

0.75 (2.60%)

08:55
01/28/19
01/28
08:55
01/28/19
08:55

Genmab says patents asserted against Darzalex in U.S. declared invalid

Genmab A/S (GMXAY) announced Saturday that the U.S. District Court of Delaware declared the three U.S. patents, asserted by MorphoSys AG (MOR) against Genmab and Genmab's collaboration partner Johnson & Johnson's (JNJ) Janssen Biotech are invalid by summary judgment. The patent infringement lawsuit was initiated by MorphoSys against Genmab and Janssen in April 2016 asserting that activities with Darzalex in the United States infringe its U.S. patents, and the case has been pending before the U.S. District Court of Delaware, the company pointed out. The summary judgment order declared all three patents invalid due to lack of enablement. As a result of this decision, the jury trial scheduled for February 2019 will not take place. MorphoSys has the opportunity to appeal the district court decision to the U.S. Court of Appeals for the Federal Circuit, it added. In addition, during the case a further claim by Janssen and Genmab was included in the case that the three MorphoSys patents were unenforceable due to inequitable conduct by MorphoSys. That issue remains to be decided.

GMXAY

Genmab ticker changed to GMAB

$0.00

(0.00%)

MOR

MorphoSys

$29.63

0.75 (2.60%)

JNJ

Johnson & Johnson

$128.23

1.16 (0.91%)

  • 18

    Feb

  • 25

    Feb

  • 06

    Mar

GMXAY Genmab ticker changed to GMAB
$0.00

(0.00%)

06/20/18
JPMS
06/20/18
UPGRADE
JPMS
Overweight
Genmab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Quigley upgraded Genmab with an increased price target of 1,150 kroner. The market is overly cautious on Darzalex competition and recent pullback in shares offers an attractive entry point, Quigley tells investors in a research note.
10/01/18
HCWC
10/01/18
INITIATION
HCWC
Buy
Genmab initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Genmab with a Buy rating and DKK 1,600 price target.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
Genmab upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Genmab to Buy and raised his price target for the shares to DKK 1,250 from DKK 1,220. The analyst says the shares are "well underpinned" by Darzalex while the company's pipeline is maturing.
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Genmab downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Genmab to Neutral with an unchanged price target of FKK 1,150. The analyst believes Darzalex's potential is largely reflected in the shares at current levels.
MOR MorphoSys
$29.63

0.75 (2.60%)

12/02/18
PIPR
12/02/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys' MOR208 ASH data 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that MorphoSys presented MOR208 data at ASH, and says she is particularly encouraged that MOR208 efficacy is consistent across of cell-of-origin and in rituximab refractory patients. "It's difficult to poke holes in the data which were deemed remarkable by the lead investigator," she contends. Brill thinks MOR208 has made it onto the radar screens of physicians and has huge potential in DLBCL. Additionally, the analyst thinks the next likely catalyst is an "attractive partnership" for MOR208 development and commercialization outside of the U.S. She reiterated an Overweight rating and $38 price target on the shares.
12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
MorphoSys upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Gunnar Romer upgraded MorphoSys (MOR) to Buy and raised his price target for the shares to EUR 130 from EUR 120. The company's 115 antibody drug candidates offer "best-in-class risk diversification and value-creation potential," Romer tells investors in a research note. Further, he believes Tremfya, which is partnered with Johnson & Johnson (J&J), is on its way to becoming a multi-billion blockbuster.
12/06/18
PIPR
12/06/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys share setup remains positive, says Piper Jaffray
Updates at MorphoSys AG's investor day were incremental, though future development plans for MOR208 in front-line diffuse large B-cell lymphoma were outlined, Piper Jaffray analyst Danielle Brill tells investors in a research note. While the analyst hoped pivotal development in the front-line setting would begin sooner than mid-2020, she appreciates "de-risking" the program by running a small study first. She continues to think the setup for MorphoSys is positive and keeps an Overweight rating on the shares with a $38 price target.
11/28/18
PIPR
11/28/18
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys's MOR208 remains key focus for company, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys following her meeting with its CEO Simon Maroney at Piper Jaffray Healthcare Conference. The analyst notes that the company remains focused on the development of MOR208 and believes that the drug could become "cornerstone" of Diffuse Large B-Cell Lymphoma, or DBLCL, therapy, remaining "very bullish" on the name. Brill adds that her survey of doctors treating lymphoma at the conference revealed that 46% would use MOR208 for their DBLCL patients.
JNJ Johnson & Johnson
$128.23

1.16 (0.91%)

01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
01/14/19
WELS
01/14/19
NO CHANGE
Target $152
WELS
Outperform
Johnson & Johnson price target lowered to $152 from $162 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered his price target for Johnson & Johnson to $152 from $162 ahead of quarterly results. The analyst forecasts Q4 sales of $20.1B and EPS of $1.97, versus consensus of $20.2B and $1.95, respectively. For 2019, Biegelsen expects initial guidance to be conservative based on the company's track record, and J&J to continue to target earnings to grow faster than sales. The analyst sees 5%-6% operational EPS growth as "reasonable." He reiterates an Outperform rating on the shares.
01/24/19
BARD
01/24/19
NO CHANGE
Target $155
BARD
Outperform
HCA Healthcare elevated to Fresh Pick at Baird
Baird analyst Matthew Gillmor elevated HCA Healthcare (HCA) to Fresh Pick ahead of its Q4 report. The analyst said recent commentary from UnitedHealth (UNH) and Johnson & Johnson (JNJ) suggest Q4 patient volumes remain solid, which he thinks will translate into EBITDA upside for HCA. Gillmor reiterated his Outperform rating and $155 price target on HCA Healthcare shares.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."

TODAY'S FREE FLY STORIES

CTST

CannTrust

$0.83

-0.085 (-9.29%)

12:30
10/14/19
10/14
12:30
10/14/19
12:30
Hot Stocks
Breaking Hot Stocks news story on CannTrust »

CannTrust Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAT

USA Technologies

$0.00

(0.00%)

12:25
10/14/19
10/14
12:25
10/14/19
12:25
Hot Stocks
USA Technologies says proposal to work with Hudson rejected by Braunstein »

USA Technologies issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYX

Alteryx

$113.99

2.33 (2.09%)

12:25
10/14/19
10/14
12:25
10/14/19
12:25
Options
Alteryx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/14/19
10/14
12:17
10/14/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
10/14/19
10/14
12:16
10/14/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

12:12
10/14/19
10/14
12:12
10/14/19
12:12
Hot Stocks
Breaking Hot Stocks news story on Hilton Grand Vacations »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

, APO

Apollo Global

$38.61

-0.11 (-0.28%)

12:11
10/14/19
10/14
12:11
10/14/19
12:11
Hot Stocks
Hilton Grand Vacations jumps after Apollo Global said to bid $40 per share »

Shares of Hilton Grand…

HGV

Hilton Grand Vacations

$32.59

-0.09 (-0.28%)

APO

Apollo Global

$38.61

-0.11 (-0.28%)

BX

Blackstone

$46.23

-0.87 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 07

    Nov

DB

Deutsche Bank

$7.57

0.1 (1.34%)

12:10
10/14/19
10/14
12:10
10/14/19
12:10
Periodicals
Deutsche Bank lavished gifts in China to win business, NY Times reports »

In a campaign to win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

, APO

Apollo Global

$38.60

-0.12 (-0.31%)

12:08
10/14/19
10/14
12:08
10/14/19
12:08
Periodicals
Breaking Periodicals news story on Hilton Grand Vacations, Apollo Global »

Apollo said to bid near…

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

APO

Apollo Global

$38.60

-0.12 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

12:06
10/14/19
10/14
12:06
10/14/19
12:06
Hot Stocks
Breaking Hot Stocks news story on Hilton Grand Vacations »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$42.08

-0.69 (-1.61%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Conference/Events
Ultragenyx participates in a conference call with JPMorgan »

Large Cap Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

GGAL

Grupo Financiero

$12.99

-0.06 (-0.46%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Conference/Events
JPMorgan telecom/networking equip analyst holds analyst/industry conference call »

Telecom & Networking…

VST

Vistra Energy

$27.00

-0.08 (-0.30%)

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$10.11

-0.99 (-8.92%)

11:50
10/14/19
10/14
11:50
10/14/19
11:50
On The Fly
SmileDirectClub drops after Dental Board of California sunset bill signed »

Shares of SmileDirectClub…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RVNC

Revance

$13.01

0.84 (6.90%)

11:47
10/14/19
10/14
11:47
10/14/19
11:47
Recommendations
Revance analyst commentary  »

Stifel surprised by CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

HAL

Halliburton

$18.43

-0.515 (-2.72%)

11:45
10/14/19
10/14
11:45
10/14/19
11:45
Options
Halliburton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

NKE

Nike

$94.87

0.97 (1.03%)

, WDC

Western Digital

$59.11

0.75 (1.29%)

11:41
10/14/19
10/14
11:41
10/14/19
11:41
On The Fly
Nike, Western Digital upgrades among today's top analyst calls »

Check out today's top…

NKE

Nike

$94.87

0.97 (1.03%)

WDC

Western Digital

$59.11

0.75 (1.29%)

TPR

Tapestry

$24.94

-1.03 (-3.97%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

XLNX

Xilinx

$96.33

0.15 (0.16%)

DAL

Delta Air Lines

$52.71

-0.23 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

SDC

SmileDirectClub

$10.33

-0.77 (-6.94%)

11:32
10/14/19
10/14
11:32
10/14/19
11:32
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INTC

Intel

$51.65

-0.41 (-0.79%)

11:28
10/14/19
10/14
11:28
10/14/19
11:28
Periodicals
Intel may skip 10nm for desktop CPUs, Wccftech reports »

Intel is planning to skip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 20

    Nov

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

, FB

Facebook

$183.97

-0.23 (-0.12%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Periodicals
Booking Holdings no longer supporting Facebook's Libra cryptocurrency, CNBC says »

CNBC Now tweeted…

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

FB

Facebook

$183.97

-0.23 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

M

Macy's

$15.17

-0.56 (-3.56%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.